JP2018510160A5 - - Google Patents

Download PDF

Info

Publication number
JP2018510160A5
JP2018510160A5 JP2017549215A JP2017549215A JP2018510160A5 JP 2018510160 A5 JP2018510160 A5 JP 2018510160A5 JP 2017549215 A JP2017549215 A JP 2017549215A JP 2017549215 A JP2017549215 A JP 2017549215A JP 2018510160 A5 JP2018510160 A5 JP 2018510160A5
Authority
JP
Japan
Prior art keywords
virus
item
composition according
composition
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017549215A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510160A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2016/023271 external-priority patent/WO2016154055A1/en
Publication of JP2018510160A publication Critical patent/JP2018510160A/ja
Publication of JP2018510160A5 publication Critical patent/JP2018510160A5/ja
Pending legal-status Critical Current

Links

JP2017549215A 2015-03-20 2016-03-18 ベクター製剤 Pending JP2018510160A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562136309P 2015-03-20 2015-03-20
US62/136,309 2015-03-20
PCT/US2016/023271 WO2016154055A1 (en) 2015-03-20 2016-03-18 Vector formulations

Publications (2)

Publication Number Publication Date
JP2018510160A JP2018510160A (ja) 2018-04-12
JP2018510160A5 true JP2018510160A5 (enExample) 2019-04-25

Family

ID=56977784

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017549215A Pending JP2018510160A (ja) 2015-03-20 2016-03-18 ベクター製剤

Country Status (6)

Country Link
US (1) US20180094280A1 (enExample)
EP (1) EP3270960A4 (enExample)
JP (1) JP2018510160A (enExample)
CN (1) CN107614008A (enExample)
AU (1) AU2016235421A1 (enExample)
WO (1) WO2016154055A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9511092B2 (en) 2013-01-28 2016-12-06 St. Jude Children's Research Hospital, Inc. Chimeric receptor with NKG2D specificity for use in cell therapy against cancer and infectious disease
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
EP3151866B1 (en) 2014-06-09 2023-03-08 Voyager Therapeutics, Inc. Chimeric capsids
SG10202007103TA (en) 2014-11-05 2020-09-29 Voyager Therapeutics Inc Aadc polynucleotides for the treatment of parkinson's disease
IL284949B2 (en) 2014-11-14 2024-06-01 Voyager Therapeutics Inc Modulatory polynucleotides
MX2017006216A (es) 2014-11-14 2018-08-29 Voyager Therapeutics Inc Composiciones y métodos para tratar la esclerosis lateral amiotrófica (ela).
WO2016094783A1 (en) 2014-12-12 2016-06-16 Voyager Therapeutics, Inc. Compositions and methods for the production of scaav
EP3258967A4 (en) 2015-02-20 2018-10-03 Ohio State Innovation Foundation Bivalent antibody directed against nkg2d and tumor associated antigens
LT3377618T (lt) * 2015-11-19 2021-02-10 Novartis Ag Buferiai, skirti lentivirusiniams preparatams stabilizuoti
WO2017096162A1 (en) 2015-12-02 2017-06-08 Voyager Therapeutics, Inc. Assays for the detection of aav neutralizing antibodies
US11299751B2 (en) 2016-04-29 2022-04-12 Voyager Therapeutics, Inc. Compositions for the treatment of disease
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
EP3458588B1 (en) 2016-05-18 2025-10-29 Voyager Therapeutics, Inc. Modulatory polynucleotides
AU2017268382B2 (en) 2016-05-18 2023-09-28 Voyager Therapeutics, Inc. Compositions and methods of treating Huntington's disease
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
ES2981519T3 (es) * 2016-11-04 2024-10-09 Takeda Pharmaceuticals Co Formulaciones de virus adeno-asociados
US20190375815A1 (en) 2017-01-31 2019-12-12 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
IL269553B2 (en) 2017-03-27 2025-10-01 Nat Univ Singapore Truncated NKG2D chimeric receptors and their uses in immunotherapy with natural killer cells
BR112019020001A2 (pt) 2017-03-27 2020-04-28 Nat Univ Singapore linhagens celulares estimuladoras para expansão ex vivo e ativação de células exterminadoras naturais
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3618839A4 (en) 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
CN111108198A (zh) 2017-05-05 2020-05-05 沃雅戈治疗公司 治疗亨廷顿病的组合物和方法
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
AU2018302016A1 (en) 2017-07-17 2020-02-06 The Regents Of The University Of California Trajectory array guide system
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
EP3687582A4 (en) 2017-09-29 2021-07-14 Voyager Therapeutics, Inc. RESCUE OF CENTRAL AND PERIPHERAL NEUROLOGICAL PHENOTYPE OF FRIEDREICH ATAXIA BY INTRAVENOUS ADMINISTRATION
WO2019079242A1 (en) 2017-10-16 2019-04-25 Voyager Therapeutics, Inc. TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
CN111479924B (zh) 2017-10-16 2024-06-14 沃雅戈治疗公司 肌萎缩性侧索硬化症(als)的治疗
SG11202003415XA (en) 2017-10-18 2020-05-28 Novartis Ag Compositions and methods for selective protein degradation
RU2020119365A (ru) 2017-11-15 2021-12-13 Новартис Аг Химерный антигенный рецептор, нацеливающийся на всма, химерный антигенный рецептор, нацеливающийся на cd19, и средства комбинированной терапии
MX2020005651A (es) 2017-11-30 2020-10-28 Novartis Ag Receptor de antigeno quimerico dirigido a bcma y usos del mismo.
CN109609533B (zh) * 2017-12-27 2020-07-10 赛德特生物科技开发有限公司 基于人源化cd276抗体的car慢病毒表达载体构建及其应用
EP3737408A1 (en) 2018-01-08 2020-11-18 Novartis AG Immune-enhancing rnas for combination with chimeric antigen receptor therapy
EP3746116A1 (en) 2018-01-31 2020-12-09 Novartis AG Combination therapy using a chimeric antigen receptor
JP7360174B2 (ja) 2018-02-09 2023-10-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における活性化キメラ受容体及びその使用
EP3752203A1 (en) 2018-02-13 2020-12-23 Novartis AG Chimeric antigen receptor therapy in combination with il-15r and il15
AU2019233917A1 (en) * 2018-03-16 2020-09-17 Cytoimmune Therapeutics, Inc. Bispecific antibody car cell immunotherapy
JP7334985B2 (ja) 2018-04-02 2023-08-29 ナショナル ユニヴァーシティー オブ シンガポール 免疫細胞で発現される膜結合抗サイトカイン非シグナル伝達バインダーによるヒトサイトカインの中和
MA52631A (fr) 2018-05-15 2021-03-24 Voyager Therapeutics Inc Compositions et méthodes pour le traitement de la maladie de parkinson
EP3796980A4 (en) 2018-05-22 2022-03-23 The Brigham & Women's Hospital, Inc. NEW THERAPY FOR ALZHEIMER'S DISEASE
US12188040B2 (en) 2018-07-30 2025-01-07 Gene Therapy Research Institution Co., Ltd. Method for enhancing gene expression using AAV vector
CN109134665B (zh) * 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
EP3845244A4 (en) * 2018-08-24 2022-09-07 Shenzhen Pregene Biopharma Co. Ltd. ANTI-BCMA SINGLE DOMAIN ANTIBODIES AND THEIR USE
AU2019330347B2 (en) 2018-08-29 2025-07-24 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
EP3844265A2 (en) 2018-08-31 2021-07-07 Novartis AG Methods of making chimeric antigen receptor-expressing cells
TW202538050A (zh) 2018-08-31 2025-10-01 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
CN109157518B (zh) * 2018-09-26 2021-03-12 厚朴生物科技（苏州）有限公司 慢病毒载体冻干保存方法及制剂
JP7528066B2 (ja) 2018-09-28 2024-08-05 ボイジャー セラピューティクス インコーポレイテッド 操作されたプロモータを有するフラタキシン発現コンストラクトおよびその使用方法
US12516349B2 (en) 2019-01-22 2026-01-06 Regeneron Pharmaceuticals, Inc. Methods and systems for manufacturing viral vectors
CN109777782A (zh) * 2019-02-15 2019-05-21 北京门罗生物科技有限公司 一种通用型car-t细胞及其制备方法和用途
CN109825526A (zh) * 2019-02-15 2019-05-31 北京门罗生物科技有限公司 一种用于通用型car-t制备的重组腺相关病毒载体及其构建方法和应用
CA3126087A1 (en) 2019-02-25 2020-09-03 Novartis Ag Mesoporous silica particles compositions for viral delivery
WO2020180882A1 (en) 2019-03-05 2020-09-10 Nkarta, Inc. Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
US20220325250A1 (en) * 2019-08-14 2022-10-13 Leukocare Ag Method for obtaining efficient compositions comprising viral vectors for vaccination or gene therapy
KR20220097492A (ko) * 2019-11-12 2022-07-07 옥스포드 바이오메디카(유케이) 리미티드 생산 시스템
CN115925976A (zh) * 2019-11-21 2023-04-07 博生吉医药科技(苏州)有限公司 Cd7-car-t细胞及其制备和应用
IL293215A (en) 2019-11-26 2022-07-01 Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
KR20220108096A (ko) 2019-11-29 2022-08-02 파로스 바이오, 인코포레이티드 신경퇴행성 질환에 대한 유전자 요법
WO2021138559A1 (en) * 2019-12-31 2021-07-08 Swanbio Therapeutics Limited Improved aav-abcd1 constructs and use for treatment or prevention of adrenoleukodystrophy (ald) and/or adrenomyeloneuropathy (amn)
TW202146441A (zh) 2020-02-27 2021-12-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
CA3173737A1 (en) 2020-02-27 2021-09-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN113549653B (zh) * 2020-04-23 2024-03-22 上海赛比曼生物科技有限公司 用于慢病毒载体长期存贮的组合试剂
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
US20240384293A1 (en) 2021-04-27 2024-11-21 Novartis Ag Viral vector production system
US20250000973A1 (en) 2021-08-20 2025-01-02 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN120112650A (zh) 2022-10-26 2025-06-06 诺华股份有限公司 慢病毒配制品

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8801338D0 (en) * 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
WO1995010601A1 (en) * 1993-10-12 1995-04-20 Chiron Viagene, Inc. Methods for preserving recombinant viruses
EP1003894A2 (en) * 1997-07-18 2000-05-31 Chiron Corporation Lentiviral vectors
DK1133316T3 (da) * 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
US6689600B1 (en) * 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) * 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
ATE471381T1 (de) * 2005-03-04 2010-07-15 Celltrion Inc Expressionsvektor für tierische zelle mit wenigstens einer kopie von mar-dna-sequenzen am 3'-ende des transkriptionsterminationsbereichs eines gens sowie verfahren zur expression eines fremdgens unter verwendung des vektors
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
JP5296775B2 (ja) * 2007-04-06 2013-09-25 インビラジェン， インコーポレイテッド 弱毒生ウイルスのための方法および組成物
JP2012519476A (ja) * 2009-03-06 2012-08-30 ヨーロピアン モレキュラー バイオロジー ラボラトリー 多タンパク質複合体のクローニング及び発現のための核酸
CN102438658A (zh) * 2009-03-13 2012-05-02 莱蒂恩公司 非整合型逆转录病毒载体疫苗
WO2011090712A2 (en) * 2009-12-28 2011-07-28 Ligocyte Pharmaceuticals, Inc. Methods for stabilizing influenza antigen enveloped virus-based virus-like particle solutions
AU2012267512B2 (en) * 2011-06-10 2014-11-20 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy
HK1203393A1 (en) * 2012-04-11 2015-10-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US9254332B2 (en) * 2013-03-15 2016-02-09 Arecor Limited Stable aqueous formulations of adenovirus vectors
CN105431456A (zh) * 2013-06-14 2016-03-23 休斯敦系统大学 用修饰的嵌合抗原受体靶向肿瘤新生血管

Similar Documents

Publication Publication Date Title
JP2018510160A5 (enExample)
RU2016145958A (ru) Химерные антигенные рецепторы с mnd-промотором
Hermanson et al. Utilizing chimeric antigen receptors to direct natural killer cell activity
HRP20200978T1 (hr) Poboljšani postupci terapije proizvodnjom adoptivnih stanica
ES2764471T3 (es) Receptores de antígeno quimérico y procedimientos de fabricación
US20180094280A1 (en) Vector formulations
JP2018526028A5 (enExample)
HRP20210116T1 (hr) Poboljšane kompozicije t stanica
JP2019500848A5 (enExample)
CN113784732A (zh) 靶向bcma的工程化免疫细胞及其用途
RU2018105963A (ru) Антитело против глипикана-3 и его применение
RU2022103665A (ru) Химерные конструкции антитело/t-клеточный рецептор и их применения
FI4063397T3 (fi) Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
WO2019061562A1 (zh) 一种增强t细胞抗肿瘤活性的核酸分子
JP2017538710A5 (enExample)
EP1885186A2 (en) Method of targeted gene delivery using viral vectors
JP2023517940A (ja) Ｗｐｒｅ変異体コンストラクト、組成物、およびその方法
EP4458419A3 (en) Methods for expanding antigen-specific car-t cells, compositions and uses related thereto
EP4004049A1 (en) Chimeric antigen receptors with mage-a4 specificity and uses thereof
JP2022536975A (ja) ＴＧＦ－β受容体及び使用方法
US12275946B2 (en) Compositions and methods for rapid cloning of t-cell receptors
CN114007626A (zh) 用于治疗癌症的组合物和方法
Smith Activation-dependent lentiviruses promote selective expansion and transduction of antigen-specific T cells
NZ741052B2 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
EA047914B1 (ru) Химерные антигенные рецепторы со специфичностью к mage-a4 и их применение